Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer

被引：15
|
作者：
Ban, Marija [1 ]
Mise, Branka Petric [1 ]
Majic, Ana [1 ]
Drazic, Ivanka [1 ]
Vrdoljak, Eduard [1 ]
机构：
[1] Univ Hosp Ctr Split, Split Sch Med, Dept Oncol & Radiotherapy, Spinciceva 1, Split 21000, Croatia
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 06期
关键词：
breast; cancer; heavily pretreated; HER2-; hormone receptor positive; metastatic; palbociclib; EVEROLIMUS PLUS EXEMESTANE; 4/6 INHIBITOR PALBOCICLIB; ENDOCRINE RESISTANCE; GROWTH-FACTOR; PHASE-II; ABEMACICLIB; COMBINATION; EXPRESSION; LETROZOLE;
D O I：
10.2217/fon-2017-0491
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: CDK4/6 inhibitors in the first and second treatment line in patients with HR+/HER2-metastatic breast cancer (mBC) in combination with hormonal therapy improve progression-free survival. Role of CDK4/6 inhibitors in further treatment lines remains unclear. Methods: Retrospective analysis of 24 HR+/HER2- heavily pretreated mBC patients is presented. Results: A total of 58.3% patients achieved stable disease. No objective response was observed. Median progression-free survival was 4.8 months; median overall survival was 11 months. Treatment was well tolerated. Conclusion: Favorable toxicity profile and efficacy of palbociclib/aromatase inhibitors combination in heavily pretreated luminal mBC patients in this study emphasize the need for further investigation of such drugs in this population.
引用
收藏
页码：537 / 544
页数：8
相关论文
共 50 条
  • [1] Efficacy and safety of everolimus for heavily pretreated patients with ER+/HER2-metastatic breast cancer.
    Osako, Tomofumi
    Nishimura, Reiki
    Nishiyama, Yasuyuki
    Fujisue, Mamiko
    Yamada, Mitsuhiro
    Suko, Kyoko
    Morioka, Junko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    [J]. ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [3] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [4] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    [J]. ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [5] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+Breast Cancer
    Shagisultanova, Elena
    Gradishar, William
    Brown-Glaberman, Ursa
    Chalasani, Pavani
    Brenner, Andrew J.
    Stopeck, Alison
    Parris, Hannah
    Gao, Dexiang
    McSpadden, Tessa
    Mayordomo, Jose
    Diamond, Jennifer R.
    Kabos, Peter
    Borges, Virginia F.
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (24) : 5021 - 5030
  • [7] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    [J]. CANCER RESEARCH, 2016, 76
  • [8] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    [J]. FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [9] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    [J]. FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [10] CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer
    Guerrero-Zotano, Angel
    Belli, Stefania
    Zielinski, Christoph
    Gil-Gil, Miguel
    Fernandez-Serra, Antonio
    Ruiz-Borrego, Manuel
    Gil, Eva Maria Ciruelos
    Pascual, Javier
    Munoz-Mateu, Montserrat
    Bermejo, Begon
    Vila, Mireia Margeli
    Anton, Antonio
    Murillo, Laura
    Nissenbaum, Bella
    Liu, Yuan
    Herranz, Jesus
    Fernandez-Garcia, Daniel
    Caballero, Rosalia
    Lopez-Guerrero, Jose Antonio
    Bianco, Roberto
    Formisano, Luigi
    Turner, Nicholas
    Martin, Miguel
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1557 - 1568
12345